PTPRC and leukemia: Moreover, in vivo administration of VS-4718 (75 mg/kg, twice per day for 16 days) in an AML mouse model reduced the leukemia burden, decreased the number of CD45+ cells in peripheral blood, and reduced the tissue infiltration of leukemia cells (34).